济南医癫痫有哪些医院(河南儿童癫病初期的症状) (今日更新中)

BEIJING, July 1 (Xinhuanet) -- China must adopt a holistic approach to addressing food safety challenges connected to the risk of contracting infectious diseases from contact with animals, the World Health Organization (WHO) has said. Peter Ben Embarek, food safety officer at WHO's China office, said the country faces risks connected to the need to produce more meat, eggs and milk to feed its growing population. He said the increased production will ramp up the risk of people being infected by food-borne diseases because of poor slaughtering oversight and the absence of proper surveillance and inspection systems. About 50 percent of pigs in China are slaughtered outside of formal facilities without the inspection of veterinarians or food safety officers. He said poorly trained producers have little or no awareness of food safety or the risk of animal diseases being passed on to humans. Such an environment could lead to the emergence of a new pandemic of influenza. During the past 60 years, 30 percent of the 335 new infectious diseases worldwide were transmitted through food, he said. Yet in many parts of China, public awareness remains low about such things. Xu Aixiang, a 35-year-old resident of Rizhao city in Shandong province, prefers to buy live poultry at local markets. Like many of her neighbors, she takes the chickens she buys home to slaughter them. "I get fresher chickens that are better quality this way," she said. "When vendors sell slaughtered chickens, the meat is no longer fresh and may have had water injected into it to make it heavier." But Ben Embarek cautioned that such live-animal markets are high-risk places for the exchange of viruses and diseases between animals and humans. He said simple and cost-effective measures can be taken to improve such markets' hygiene standards, such as the installation of separate areas to keep live poultry away from customers as well as improving air flow and waste management. Several UN agencies, including the WHO and the Food and Agriculture Organization, called on China to adopt an integrated approach to preventing emerging epidemic diseases and maintaining ecosystem integrity at an event themed "One Health" that convened on Wednesday in Beijing. At the gathering, representatives from the Ministry of Health, the Ministry of Agriculture and the Chinese Center for Disease Control and Prevention shared experiences from efforts to mitigate the H5N1 and H1N1 influenza outbreaks in China and said they were committed to working together in the future. Su Jingliang, an associate professor of preventive veterinary medicine at China Agricultural University, said his lab had detected the outbreak of a new type of flavivirus in ducks that led to a significant fall in egg production at farms in Beijing as well as in Hebei, Jiangxi and Shandong provinces. The pandemic was brought under control in March. No cases of humans contracting the disease have been reported so far but Su said he was concerned about the possibility of farmers becoming infected through close contact and long exposure to sick ducks. He said precautionary measures should be taken in cooperation with the Ministry of Health and other government agencies and checks should be run on people who are at high risk. Xu Wei contributed to this story.

SAN FRANCISCO, Aug. 9 (Xinhua) -- Nokia is planning to stop selling its low-end phones and smartphones in the United States, instead focusing on products using Microsoft's Windows Phone platform, U.S. media reported on Tuesday.The Finnish handset maker will end sales of its low-end Series 40 phones and smartphones based on the Symbian mobile operating system in the United States and Canada, as it needs to put all of its efforts into the Windows Phone products which are due out later this year, Chris Weber, head of Nokia's U.S. subsidiary, told technology news site All Things Digital."When we launch Windows Phones we will essentially be out of the Symbian business, the S40 business, etc.," Weber said.Staff members speak to trade visitors at the Nokia booth at the CommunicAsia expo in Singapore June 21, 2011.In February, Nokia and Microsoft announced plans to form a broad strategic partnership, under which Nokia agrees to adopt Windows Phone as its principal smartphone strategy.North America is a priority for Nokia, Weber noted, in part because it is a key market for Microsoft and also because Nokia sees it as a key to winning in the smartphone battle globally."We'll develop for North America and make the phones globally available and applicable," Weber said.In another development, technology blog Engadget and other U.S. media on Tuesday reported that Nokia will not bring N9, its first smartphone running the Linux-based mobile operating system MeeGo, to the U.S. market."After the very positive reception to the launch of the Nokia N9, the product is now being rolled out in countries around the world. At this time we will not be making it available in the U.S., " Nokia said in a statement.

SAN FRANCISCO, June 9 (Xinhua) -- Hewlett-Packard Co. (HP) on Thursday announced that its tablet computer, HP TouchPad, will go on sale in the United States on July 1.Two versions of HP TouchPad, with the option of either 16 gigabytes or 32 gigabytes of internal storage, and both only with Wi-Fi connection, will be available in the United States for 499. 99 U.S. dollars and 599.99 dollars respectively, the company said in a statement.The product will hit stores in Britain, Ireland, France and Germany a few days later and in Canada in mid-July, with availability scheduled to follow later this year in Italy, Spain, Australia, China's Hong Kong, New Zealand and Singapore.Preorders in North America and Europe will begin on June 19, HP said.HP did not release the price details when it introduced TouchPad on Feb. 9. The black device, with a 9.7-inch touch screen, runs webOS operating system, a mobile platform developed by Palm, a smartphone maker acquired by HP last April for 1.8 billion dollars.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 4 (Xinhua) -- China's railway system has transported some 1.27 billion passengers during the first eight months of this year, up 11.8 percent from a year earlier, the Ministry of Railways said Sunday.The figure has accounted for 67.4 percent of the ministry's full-year target, said the ministry in a statement on its website.The Ministry of Railways has planned to send 1.9 billion passengers in 2011, up 13.1 percent year-on-year.The country's high-speed trains had been operating with improved order and efficiency, said the ministry, which has been required to run high-speed trains at slower speeds, as well as to reorganize bullet train schedules nationwide, for safety reasons.The State Council, or Cabinet, ordered increased safety checks after a fatal train collision that killed 40 people in July raised concerns over the safety of the country's high-speed railways.The ministry cut the number of high-speed trains running between Beijing and Shanghai to 66 pairs from 88 pairs per day, effective as of Aug. 16.Meanwhile, the railways transported more than 2.6 billion metric tons of goods from January to August, up 7.8 percent year-on-year, the ministry said.

来源：资阳报